**Editor**

Tore K Kvien

Associate EditorsFrancis Berenbaum
Hans Bijlsma
Dimitrios Boumpas
Gerd Burmester
Mary Crow**Editorial office**Annals of the Rheumatic Diseases
University Medical Centre Nijmegen
Department of Rheumatology
PO BOX 9101
6500 HB Nijmegen
The Netherlands
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com

ISSN: 0003-4967 (print)

ISSN: 1468-2060 (online)

Impact Factor: 6.411

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2008 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd, typeset by The Charlesworth Group and printed in the UK on acid-free paper from sustainable forests by Cambrian Printers Limited, Aberystwyth, UK

Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: Annals of the Rheumatic Diseases, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA

Advances in targeted therapies X**Preface**

- iii1** Advances in targeted therapies X
F C Breedveld, J R Kalden, J S Smolen

Consensus statement

- iii2** Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008
D E Furst, E C Keystone, B Kirkeham, R Fleischmann, P Mease, F C Breedveld, J S Smolen, J R Kalden, G R Burmester, J Braun, P Emery, K Winthrop, B Bresnihan, F De Benedetti, T Dörner, A Gibofsky, M H Schiff, J Sieper, N Singer, P L C M Van Riel, M E Weinblatt, M H Weisman

Tolerance and inflammation

- iii26** Th17 cells in immunity and autoimmunity
M Oukka

Clinical outcomes assessment

- iii30** Why do people with rheumatoid arthritis still die prematurely?
S E Gabriel

New cell and cytokine targets II

- iii35** Stem cell transplantation: a treatment option for severe systemic sclerosis?
J M van Laar, D Farge, A Tyndall


- iii39** Alloreactive natural killer cells in targeting high-risk leukaemias
L Moretta, F Locatelli, A Moretta

Innate immunity and autoimmunity

- iii44** Phagocytosis and antigen presentation: a partnership initiated by Toll-like receptors
J M Blander
- iii50** Adding fuel to fire: microRNAs as a new class of mediators of inflammation
F J Sheedy, L A J O'Neill
- iii56** Lessons from multiple sclerosis: models, concepts, observations
H Wekerle

Translational medicine: brief reports

- iii61** Protection against rheumatoid arthritis by HLA: nature and nurture
A L Feitsma, A H M van der Helm-van Mil, T W J Huizinga, R R P de Vries, R E M Toes
- iii64** Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies
L H Calabrese, E S Molloy

Take the pain out of research every month

Annals of the Rheumatic Diseases is the premier clinical rheumatology journal in Europe with an impressive impact factor of 5.767, so you'll want the guarantee of reading it every month.

Why not recommend the journal to your librarian or better still, obtain your own personal subscription? You will receive a paper copy every month as well as online access for just £212 a year (€314, \$403). Too much paper on your desk already? An online subscription is just £99 (€147, \$188).

Visit group.bmj.com/group/subs-sales - your subscription to this first class journal is just a few clicks away.

ard.bmj.com BMJ Journals

iii66 Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction
J Kay

iii70 The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications
T Weichhart, M D Säemann

Osteoarthritis

iii75 Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism
M B Goldring, M Otero, K Tsuchimochi, K Ijiri, Y Li

New cell and cytokine targets ii

iii83 Interleukin 21 as a target of intervention in autoimmune disease
R Ettinger, S Kuchen, P E Lipsky

iii87 How to cope with pathogenic long-lived plasma cells in autoimmune diseases
B F Hoyer, I M Mumtaz, T Yoshida, F Hiepe, A Radbruch

iii90 Tolerogenic dendritic cells for autoimmune disease and transplantation
A W Thomson, P D Robbins

Biological and clinical markers

iii97 Epigenetic mechanisms in health and disease
S M van der Maarel